These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 27357249

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang T, Pan S, Sun X, Xu L.
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
    Liu X, Xiao XY, Shou QY, Yan JF, Chen L, Fu HY, Wang JC.
    J Ethnopharmacol; 2016 Dec 04; 193():538-545. PubMed ID: 27686271
    [Abstract] [Full Text] [Related]

  • 9. Bufalin inhibits peritoneal dissemination of gastric cancer through endothelial nitric oxide synthase-mitogen-activated protein kinases signaling pathway.
    Zou D, Song J, Deng M, Ma Y, Yang C, Liu J, Wang S, Wen Z, Tang Y, Qu X, Zhang Y.
    FASEB J; 2021 May 04; 35(5):e21601. PubMed ID: 33913201
    [Abstract] [Full Text] [Related]

  • 10. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
    Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y, Tong J, Li JM, Wu YL, Yan H.
    Cell Death Dis; 2017 May 11; 8(5):e2776. PubMed ID: 28492559
    [Abstract] [Full Text] [Related]

  • 11. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Jiang S, Chang H, Deng S, Fan D.
    Int J Oncol; 2019 Jun 11; 54(6):1933-1942. PubMed ID: 31081049
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
    Lu R, Zhao G, Yang Y, Jiang Z, Cai J, Hu H.
    Technol Cancer Res Treat; 2019 Jan 01; 18():1533033819864311. PubMed ID: 31405336
    [Abstract] [Full Text] [Related]

  • 13. Flotillin-1 promotes progression and dampens chemosensitivity to cisplatin in gastric cancer via ERK and AKT signaling pathways.
    Wei J, Wang R, Lu Y, He S, Ding Y.
    Eur J Pharmacol; 2022 Feb 05; 916():174631. PubMed ID: 34774850
    [Abstract] [Full Text] [Related]

  • 14. Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway.
    Zhou D, Liu W, Liang S, Sun B, Liu A, Cui Z, Han X, Yuan L.
    Cancer Med; 2018 Apr 05; 7(4):1369-1383. PubMed ID: 29522284
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis.
    Li B, Tan S, Yu X, Wang Y.
    Biochem Biophys Res Commun; 2024 Nov 12; 733():150440. PubMed ID: 39067250
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.